CANCER:

Hodgkin Lymphoma

Related cancers:

‹

Lymphoma (801)

Non-Hodgkin’s Lymphoma (707)

Lymphoma (801)

Non-Hodgkin’s Lymphoma (707)

›

TNFRSF8 positive TNFRSF8 positive	Hodgkin Lymphoma HL	brentuximab vedotin Sensitive: A1 - Approval
No biomarker No biomarker	Hodgkin Lymphoma HL	pembrolizumab Sensitive: A1 - Approval
No biomarker No biomarker	Hodgkin Lymphoma HL	carmustine Sensitive: A1 - Approval
No biomarker No biomarker	Hodgkin Lymphoma HL	brentuximab vedotin Sensitive: A1 - Approval
No biomarker No biomarker	Hodgkin Lymphoma HL	nivolumab Sensitive: A1 - Approval
No biomarker No biomarker	Hodgkin Lymphoma HL	bendamustine Sensitive: A1 - Approval
No biomarker No biomarker	Hodgkin Lymphoma HL	R-CHOP Sensitive: A2 - Guideline
No biomarker No biomarker	Hodgkin Lymphoma HL	rituximab Sensitive: A2 - Guideline
No biomarker No biomarker	Hodgkin Lymphoma HL	R-CVP Sensitive: A2 - Guideline
No biomarker No biomarker	Hodgkin Lymphoma HL	bortezomib Sensitive: A2 - Guideline
No biomarker No biomarker	Hodgkin Lymphoma HL	everolimus Sensitive: A2 - Guideline
No biomarker No biomarker	Hodgkin Lymphoma HL	carboplatin + etoposide oral + bendamustine Sensitive: A2 - Guideline
No biomarker No biomarker	Hodgkin Lymphoma HL	nivolumab + brentuximab vedotin Sensitive: A2 - Guideline
No biomarker No biomarker	Hodgkin Lymphoma HL	lenalidomide Sensitive: A2 - Guideline
No biomarker No biomarker	Hodgkin Lymphoma HL	GemOx Sensitive: A2 - Guideline
No biomarker No biomarker	Hodgkin Lymphoma HL	ICE Sensitive: A2 - Guideline
No biomarker No biomarker	Hodgkin Lymphoma HL	ESHAP Sensitive: A2 - Guideline
No biomarker No biomarker	Hodgkin Lymphoma HL	DHAP Sensitive: A2 - Guideline
No biomarker No biomarker	Hodgkin Lymphoma HL	R-ESHAP Sensitive: A2 - Guideline
No biomarker No biomarker	Hodgkin Lymphoma HL	MINE Sensitive: A2 - Guideline
CHD8 mutation CHD8 mutation	Hodgkin Lymphoma HL	sintilimab Resistant: C3 – Early Trials
CELF2 mutation CELF2 mutation	Hodgkin Lymphoma HL	sintilimab Resistant: C3 – Early Trials
ABCC2 underexpression ABCC2 underexpression	Hodgkin Lymphoma HL	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials
PD-1 underexpression PD-1 underexpression	Hodgkin Lymphoma HL	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials
CD163 overexpression CD163 overexpression	Hodgkin Lymphoma HL	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials
CD14 overexpression CD14 overexpression	Hodgkin Lymphoma HL	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials
TNFRSF8 positive TNFRSF8 positive	Hodgkin Lymphoma HL	Sensitive: C3 – Early Trials
TNFRSF14 mutation TNFRSF14 mutation	Hodgkin Lymphoma HL	sintilimab Resistant: C3 – Early Trials
MHC-II expression MHC-II expression	Hodgkin Lymphoma HL	nivolumab Sensitive: C3 – Early Trials
CASP3 underexpression + BCL2 positive CASP3 underexpression + BCL2 positive	Hodgkin Lymphoma HL	ABVD Resistant: C3 – Early Trials
CASP3 overexpression CASP3 overexpression	Hodgkin Lymphoma HL	ABVD Sensitive: C3 – Early Trials
BCL2 expression BCL2 expression	Hodgkin Lymphoma HL	ABVD Resistant: C3 – Early Trials
CASP3 overexpression + BCL2 negative CASP3 overexpression + BCL2 negative	Hodgkin Lymphoma HL	ABVD Sensitive: C3 – Early Trials
B2M mutation B2M mutation	Hodgkin Lymphoma HL	sintilimab Resistant: C3 – Early Trials
TNFRSF8 overexpression TNFRSF8 overexpression	Hodgkin Lymphoma HL	nivolumab + brentuximab vedotin Sensitive: C3 – Early Trials
Chr amplification(9)(p24.1) Chr amplification(9)(p24.1)	Hodgkin Lymphoma HL	nivolumab Sensitive: C3 – Early Trials
BCL2 overexpression BCL2 overexpression	Hodgkin Lymphoma HL	venetoclax Resistant: D – Preclinical
CD123 positive CD123 positive	Hodgkin Lymphoma HL	VIP943 Sensitive: D – Preclinical
BCL2 expression BCL2 expression	Hodgkin Lymphoma HL	venetoclax Sensitive: D – Preclinical
XPO1 E571K XPO1 E571K	Hodgkin Lymphoma HL	venetoclax + selinexor Sensitive: D – Preclinical
XPO1 E571K XPO1 E571K	Hodgkin Lymphoma HL	venetoclax Sensitive: D – Preclinical

Hodgkin Lymphoma

Associations(41)

Associations
(41)